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Abstract 
Background: Survivin is a newly found member of the inhibitors of apoptosis proteins, which plays a certain role 
in cancer. Survivin has a distinctly different expression in cancers, including prostate cancer. We are searching for the 
relationship between survivin levels in normal prostate tissue, benign prostate hyperplasia (BPH), and prostate adeno-
carcinoma in this study.
Results: The study surveyed 282 prostate samples, 94 normal, 94 BPH, and 94 prostate adenocarcinoma samples. 
Survivin expression was absent in normal prostate tissues. In the BPH group, the survivin expression level was higher 
than that of the normal group. In the adenocarcinoma group, the survivin expression level was higher than that of the 
BPH group. There was a significant association between survivin expression level and the adenocarcinoma stage.
Conclusion: Although there is no expression of survivin in normal prostate tissue, its expression is slightly positive in 
BPH. High survivin expression is related to a higher Gleason score in the adenocarcinoma of the prostate.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
The inhibitors of apoptosis (IAP) proteins are a group 
of proteins that mediate several pathways, including cell 
cycle, immunity, inflammation, and cell death (de Alma-
gro and Vucic 2012). One of the recently discovered IAP 
proteins is survivin. It is the smallest member in the IAP 
family and is mainly expressed in the fetal tissue but has 
a known role in many cancers, such as bladder cancer, 
non-small cell lung cancer, esophageal cancer, breast 
carcinoma, gastric carcinoma, recurrent colorectal car-
cinoma, rectal cancer, neuroblastoma, and prostate can-
cer (Ambrosini et al. 1997; Kishi et al. 2004). Survivin is 
somehow unique in the IAP family, because of its struc-
ture and its definite difference of expression in cancer, 
including prostate cancer tissue as compared the normal 
tissue. Survivin is also associated with cancer prognosis 
and progression (Zhang et al. 2009). The absence of sur-
vivin in normal tissues and its over expression in tumors, 
and the correlation of survivin and poor prognosis of 
cancer, attracts many researchers to evaluate its potential 
therapeutic and diagnostic values (Lladser et al. 2011).
Since 1966, Gleason Grading is used in evaluation 
prostate cancer and it is the strongest prognostic factor 
in prostate cancer (Gleason 1966; Sauter et al. 2016). Its 
strong feature is that it is not influenced by cellular mor-
phology and is based on the cancer features. Although 
tumor volume and PSA level increase may trigger treat-
ment, the main treatment criteria is a Gleason score of 7 
or more (Komisarenko et al. 2016). The Gleason grading 
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system was updated in 2005 at a consensus conference 
of international experts in urological pathology (Epstein 
2010) and they agreed that Gleason score between 2 and 
4 should not be given on prostate biopsies. This update is 
currently recommended in international guidelines.
Studies have shown that the level of survivin expression 
gradually increases from normal prostate tissue and low 
risk prostate cancer to high risk prostate cancer and is 
highest in metastatic prostate cancer (Shariat et al. 2004). 
Some studies show that survivin has a higher expression 
in benign prostatic hypertrophy (BPH) and that it corre-
lates with BPH parameters (Shariat et al. 2005). However, 
there are also some studies that confirm that the level of 
survivin in BPH is not higher than that in normal pro-
static tissue (Yu et  al. 2010). Although few studies have 
been conducted to clarify the relationship between sur-
vivin and the grading of prostate cancer, this relation 
appears contradictory. If this relationship is definite, we 
can use survivin as a prognostic factor and therapeutic 
target. In this study, we are searching for the relationship 
between survivin level in normal prostate tissue, BPH, 
and prostate adenocarcinoma.
Methods
The study sample size was calculated on the basis of the 
survivin level in BPH and the adenocarcinoma of the 
prostate in a previous study by Rodríguez-Berriguete 
et  al. (Rodríguez-Berriguete et  al. 2010). We assumed 
that there is no survivin expression in normal prostate 
samples. According to the 95 % confidence interval and 
power of 20  %, the sample size was calculated as 94 in 
each group (normal prostate, BPH, and adenocarcinoma 
of the prostate).
Samples obtained using prostatectomy or TURP and 
adenocarcinoma and BPH samples diagnosed on the 
basis of H&E staining. Samples from biopsies were not 
included in our study, because of the small size of the 
samples, that could negatively affect the accuracy of 
staining and Gleason grading. Normal prostate samples 
obtained from normal glands adjacent to adenocarci-
noma or BPH tissue, are consistent with the method 
employed by Shariat et al. (Shariat et al. 2004).
These samples were obtained from patients admitted to 
Shahid Beheshty Hospital between 2002 and 2014. Nor-
mal prostate and BPH sampling was based on a table of 
random numbers from the patients admitted to the same 
hospital during the same period. All prostate samples 
archived in the pathology ward which had no history of 
urinary tract infection and prostatitis were included in 
the study. All of the cases with incomplete and damaged 
data, with improper staining, and results obtained via 
needle biopsy were excluded. There are some reports that 
suggest inflammation as a trigger of increased survivin 
expression in prostate cells (St. Sauver and Jacobsen 
2008), therefore, samples with infiltration of inflamma-
tory cells were also excluded from our study.
Samples were obtained with the usual method of sam-
pling (Dabbs 2013): 5-µm paraffinated blocked sections 
were obtained from all prostate samples. Haematoxyli-
nEosine (H&E) and Immunohistochemistry (IHC) meth-
ods used after sample preparation: (1) Samples were 
subjected to 60 °C for 2 h. (2) Rehydration was conducted 
with xylolose, alcohol, and distilled water for 15  min, 
10 min, and 5 min, respectively. (3) Endogenous peroxi-
dase activity removal: samples were put in 3 % hydrogen 
peroxidase for 20 min and washed with phosphate-buff-
ered saline twice, for 5 min each time.
(4) Antigen retrieval: Samples are paled in a citrate 
puffer (pH 6) and in the autoclave of 134° and 1.5–2 bar 
pressure for 10  min. They are then let to cool at room 
temperature for 20  min and wash with distilled water 
thereafter. (5) Primary survivin antibody is added to the 
samples for 1  h. (6) They are washed with phosphate-
buffered saline (PBS) three times for 5  min each time. 
(7) Secondary antibody is added and placed for 30  min 
at room temperature. (8) PBS washing. (9) 3,3′-diamin-
obenzidine (DAB) chromogen: samples are placed in the 
diluted solution for 10 min (1.9 DAB with DAB substance 
ratio). (10) Hematoxylin staining of the background for 
1  min, followed by washing. (11) Dehydration of the 
slides with 96 % alcohol and 100 % xylol, every two sides, 
10 min each side. (12) Mounting of the slides in prepara-
tion for viewing under the light microscope.
Histopathological diagnosis of the H&E stained slides 
are determined and the parts with no pathological find-
ings are considered normal (Fig. 1). Normal prostate tis-
sue is made of separate, small, regular glands with one 
epithelial and one basal cell layer. We can see a glandu-
lar hyperplasia, cystic and dilated glands, multi-layer 
epithelium or papillary formation in BPH. In the adeno-
carcinoma slides, diagnosis was based upon the Gleason 
criteria. Final grading is the sum of primary (dominant 
appearance of the tumor) and secondary (other sites 
of the tumor) survivin grading. IHC evaluation of the 
stained slides comprised two groups of positive and nega-
tive. Positive samples were categorized as +1, +2, and +3 
groups. No staining or weak staining of up to 10 % of the 
cells was considered negative. Weak to moderate staining 
in 10–29 % of the cells was considered +1. Moderate to 
intense staining in 30–49  % of the cells was considered 
2+. Intense staining in more than 50 % of the cells was 
considered 3+. Intensity of staining was evaluated by two 
pathologists. If they did not categorize a sample similarly, 
the third pathologist categorized the sample. According 
to the guidelines on the antibody kit, bladder transitional 
carcinoma cell was considered a positive control and 
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normal cervix tissue a negative control. H&E and IHC 
staining were synchronously and similarly conducted on 
all the samples and on the positive and negative control 
simultaneously.
All collected data, including histopathological diagno-
sis, tumor grade, IHC results (positive or negative), and 
staining intensity were recorded, along with the patients’ 
age and serum PSA level.
Statistical analysis
All collected data were analyzed using SPSS version 17. 
We described survivin and other variables according 
to their distribution. We compared the survivin level 
between groups using the Chi squared test. Logistic 
regression analysis was used to remove the confounding 
factors. p was considered significant at the level of 0.05.
Results
This study surveyed 282 prostate samples: 94 normal, 
94 BPH, and 94 prostate adenocarcinoma samples. The 
patients’ mean (SD) age in the normal, BPH, and adeno-
carcinoma groups were 73.7 (8.9), 72.4 (7.6), and 75.6 
(7.9) years, respectively. Demographic data of each group 
can be found in Table 1.
All samples in the normal prostate group were stained 
less than 10  % for survivin and considered negative. In 
the BPH group, 7 samples (7.4 %) were negative, 32 sam-
ples (34 %) were 1+, 45 (47.9 %) were 2+, and 10 (10 %) 
were 3+. In the adenocarcinoma group, 1 sample (1.1 %) 
was negative, 16 (14.9 %) were 1+, 35 (37.2 %) were 2+, 
and 44 (46.8  %) were 3+ for survivin (Fig.  1). Figure  2 
shows different levels of survivin staining. The variation 
of survivin expression between these three groups was 
considered meaningful, thus there is a statistical differ-
ence between survivin expression in normal, BPH and 
adenocarcinoma (p < 0.01) (Table 2).
These three groups were compared separately. It was 
found that survivin levels in the adenocarcinoma group 
were considerably greater than those in the normal 
group. Comparing the survivin levels of the BPH and 
adenocarcinoma groups with the normal group revealed 
a significant difference (p < 0.001).
The risk of adenocarcinoma, comparing BPH group, is 
increased 3.1 times (95 % CI: 2.0, 4.8) with every level of 
survivin increasing and after adjusting according to age, 
this relation stayed unchanged. Adenocarcinoma samples 
were graded according to the Gleason staging criteria. 
There were 19 samples (20.2 %) in the grade 7 and it was 
Fig. 1 Different levels of survivin staining in the samples. a Negative, <10 % of epithelial cells weakly stained, b 1+, 10–29 % of epithelial cells 
stained weakly to moderate, c 2+, 30–49 % of epithelial cells stained moderately to intensive, d 3+, more than 50 % of epithelial cells stained 
intensely
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the most prevalent grade among all grades. All the seven 
samples in grade 10 were 3+ stained for survivin expres-
sion. In the adenocarcinoma samples, there was only one 
sample with negative staining for survivin. The Gleason 
grade of this patient was four (Table 3).
The higher the Gleason grade, the greater the degree 
of survivin expression staining. Most (60.4  %) of the 
adenocarcinoma samples with Gleason grade of ≥7 were 
3+ positive for survivin. The chance of a Gleason grade 
of ≥7 in the patients with 3+ staining was 3.15 times in 
patients with staining <50 % (Tables 4, 5).
Survivin expression up to 30 % (negative and 1+ degree 
in our staging) is associated with a slight increase in ade-
nocarcinoma staging; however, this association is more 
apparent in the upper percentages of survivin expression. 
This correlation is considerable overall.
The relation of the PSA level and survivin expression 
was statistically significant (p  <  0.001) (Table  6). Most 
of the samples with a PSA of >10 (42.3 %) had a 3 + sur-
vivin expression, but the samples with a PSA of <4 only 
had 5.5  % of 3+ survivin expression. Age did not exert 
a considerable effect on survivin expression in BPH and 
adenocarcinoma groups (p > 0.05). 
Table 1 Demographic data of  cases in  different histo-
pathological groups
Group Normal BPH Adenocarcinoma
Age (mean ± SD) 74 ± 9 72 ± 8 76 ± 8
Age range 50–95 50–89 52–95













Negave 1+ 2+ 3+
Fig. 2 Survivin expression percentage levels in different histopatho-
logical groups of prostate samples
Table 2 Survivin expression levels in different histopathological groups of prostate samples
* Pearson Chi Square test
Histology Survivin level (%) p value*
Negative 1+ 2+ 3+ Total
Normal 94 (100) 0 0 0 94 (100) <0.001
BPH 7 (7.4) 32 (34) 45 (47.9) 10 (10.6) 94 (100)
Adenocarcinoma 1 (1.1) 14 (14.9) 35 (37.2) 44 (46.8) 94 (100)
Total 102 (36.2) 46 (16.3) 80 (28.4) 54 (19.1) 282 (100)
Table 3 Gleason staging of  adenocarcinoma and  survivin 
expression
Gleason stage Survivin expression (%)
Negative 1+ 2+ 3+ Total
2 0 4 (57.1) 2 (28.6) 1 (14.3) 7 (7.4)
3 0 3 (42.9) 2 (28.6) 2 (28.6) 7 (7.4)
4 1 (10) 0 7 (70) 2 (20) 10 (10.6)
5 0 3 (27.3) 4 (36.4) 4 (36.4) 11 (11.7)
6 0 1 (9.1) 4 (36.4) 6 (54.5) 11 (11.7)
7 0 2 (10.5) 9 (47.4) 8 (42.1) 19 (20.2)
8 0 1 (6.7) 3 (20) 11 (73.3) 15 (16)
9 0 0 4 (57.1) 3 (42.9) 7 (7.4)
10 0 0 0 7 (100) 7 (7.4)
Total 1 (1.1) 14 (14.9) 35 (37.2) 44 (46.8) 94 (100)
Table 4 Comparing survivin expression and Gleason grad-
ing of >7
Gleason stage Survivin
Less than 3+ (%) 3+ (%) Total
<7 31 (62) 15 (34.1) 46 (48.9)
≥7 19 (38) 29 (65.9) 48 (51.1)
Total 50 (100) 44 (100) 94 (100)
Table 5 Comparing the Gleason grading of  >7 with  sur-
vivin expression




<3+ 31 (67.4) 19 (39.6) 50 (53.2) 3.15 (1.35–7.35) 0.008
3+ 15 (32.6) 29 (60.4) 44 (46.8)
Total 46 (100) 48 (100) 94 (100)
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Discussion
This study evaluates the expression of survivin protein in 
prostate samples with the IHC method. According to our 
results, the expression of survivin was negative in the nucleus 
of normal prostate samples cells, slightly positive in the BPH 
sample cells, and associated with Gleason staging in the 
adenocarcinoma group. There is a significant correlation 
between nuclear and cytoplasmic survivin staining (Zhang 
et al. 2009), which is comparable with the results of studies 
evaluating the cytoplasmic and nuclear survivin levels.
Some studies used normal prostate tissues biopsies 
(Rodríguez-Berriguete et  al. 2010). Normal autopsies 
could not be used in this study, however, owing to meth-
odological limitations. We could not obtain autopsies 
because the families did not consent.
The results of absence of survivin expression in normal 
prostate tissues are consistent with other studies (Shariat 
et al. 2004; Rodríguez-Berriguete et al. 2010). There was a 
similar negative expression of survivin in these studies in 
the normal epithelial prostate glands.
In our study, in prostate adenocarcinoma, the sur-
vivin expression was higher than BPH and this result is 
in accordance with the results of Rodríguez-Berriguete 
et al. (Rodríguez-Berriguete et al. 2010), but the study by 
Yu et al. (2010) suggests that survivin expression in BPH 
does not differ significantly from normal prostate tissue. 
However according to our study we cannot efficiently 
use 3+ surviving staining for differentiating adenocar-
cinoma and BPH samples. Using other markers such as 
alpha-methylacyl CoA racemase and myoepithelial mark-
ers such as 34βE12 and P63 appears more functional to 
differentiate between these two anomalies (Carswell 
et al. 2006; Kalantari et al. 2014). Survivin is expressed in 
other tumor types (Shintani et al. 2013; Fukuda and Pelus 
2006), and thus, cannot be used in locating the tumor’s 
origin in metastasis with an unknown origin.
The results of this study showed that malignant pros-
tate carcinoma (based on the Gleason criteria) and sur-
vivin expression co-occur, as Shariat et  al. suggested. 
However, our results are not in accordance with those of 
Rodríguez-Berriguete et  al. (Rodríguez-Berriguete et  al. 
2010). Most patients (60.41  %) with a Gleason score of 
≥7 were positive for survivin with a 3+ scale; thus, high 
survivin expression is related to a higher Gleason score. 
We found the chance of a Gleason grade of ≥7 in the 
patients with 3+ staining was 3.15 times in patients with 
staining <50  %. Although, we excluded the cases with 
UTI and inflammation to lower the confounding factors, 
however, the cases were not screened for other malignan-
cies, which may in part, increase the survivin expression. 
Moreover, the effects of age has been considered, and 
after adjusting according to age, the results remained 
unchanged.
We used the IHC grading developed by Shariat et  al. 
(Shariat et al. 2004). Other computer analytical and man-
ual methods also exist (Shinde et al. 2014). For example 
Dabbs et  al. (Dabbs 2013) uses the Histochemical score 
(H score) for hormonal receptors in breast tumors and 
counts the non-stained nucleases. This score ranges from 
0 to 300. This method was used by Mazieres et al. for the 
expression of EGFR in lung tumors with IHC (Mazières 
et al. 2013).
Besides we can use survivin as a prognostic factor, 
there are therapeutic advantages of measuring it. Sur-
vivin can show chemotherapeutic resistance to cisplatin, 
bortezomib, vincristine, tamoxifen, TNF-a and TRAIL 
in tumor cells (Cheung et al. 2010; Liu et al. 2010; Zhang 
et  al. 2006; Ling et  al. 2010). There is also reports that 
survivin suppresses radiation-induced apoptosis (Solei-
manpour and Babaei 2015), so, targeting survivin can 
increase the sensitivity to radiotherapy in cancer patients.
The retrospective nature of this study can be counted 
as a limitation, and a prospective study with other grad-
ing methods would further clarify the subject. We could 
not screen the patients for other tumor types as survivin 
has been suggested as a progression factor in some can-
cers, including bladder (Zhang et al. 2016), colon (Li et al. 
2016) and breast (Liu et al. 2016). Prospective studies can 
lessen these confounding factors. Although studies on 
prostate cancer can reveal the prognostic and therapeutic 
importance of survivin, further studies on survivin level 
in different cancers would make a valuable therapeutic 
and prognostic target for treating patients with other 
cancers, as well.
Table 6 Serum PSA level and survivin expression correlation
* Pearson Chi square test
PSA Survivin level p*
Negative 1+ 2+ 3+ Total
<4 26 (28.6) 27 (29.7) 33 (36.3) 5 (5.5) 91 <0.001
4–9.9 57 (41) 17 (12.2) 38 (27.3) 27 (19.4) 139
≥10 19 (36.5) 2 (3.8) 9 (17.3) 22 (42.3) 52
Total 102 (36.2) 46 (16.3) 80 (28.4) 54 (19.1) 282
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Conclusion
We may conclude that there is no expression of survivin 
in normal prostate tissue but that its expression is slightly 
positive in the BPH and it is associated with Gleason 
staging. High survivin expression is related to a higher 
Gleason score in the adenocarcinoma of the prostate. 
Survivin detection with the IHC method is unhelpful for 
differentiating adenocarcinoma of the prostate and BPH.
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